Exchange: NASDAQ·Updated 07:52 PM EST

OMER News

News
all
press releases
Omeros (NASDAQ:OMER) Shares Break Below Two Hundred Day Moving Average - Time to Sell?
Omeros (NASDAQ:OMER) Share Price Breaks Below 200-Day Moving Average - Should You Sell...
MarketBeat
Omeros (NASDAQ:OMER) Shares Break Below Two Hundred Day Moving Average - Time to Sell?
Omeros (NASDAQ:OMER) Share Price Breaks Below 200-Day Moving Average - Should You Sell...
MarketBeat
More News
Wall Street Zen cut Omeros from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat
Omeros: Yartemlea Commercial Momentum Supports Upgrade Despite Q3 Deceleration (Rating Upgrade...
SeekingAlpha
Omeros Corporation (NASDAQ:OMER - Free Report) - Investment analysts at HC Wainwright raised their FY2027 earnings estimates for Omeros in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of $0.3...
MarketBeat
CEO Demopulos said the company is now shifting its near-term regulatory strategy outside the European Union.
Stocktwits
Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell...
MarketBeat
HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Omeros in a research report on Tuesday...
MarketBeat
U.S. stock futures fell as Red Cat plunged 25.8% after weak Q3 results and withdrawing FY26 guidance; several stocks also declined premarket.read more...
Benzinga
Anthropic’s public listing, expected on Wednesday, could top $1.4 trillion in valuation, stoking a key test for Wall Street's AI appetite.
Stocktwits
Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss. YARTEMLEA generated $35.9 million...
MarketBeat

Advertisement|Remove ads.